Nanotransposon Vector Design for High-Efficiency Gene Transfer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a long-felt need for improved transposition methods in gene therapy that enhance the efficacy and efficiency of gene transfer into human cells, particularly for use in molecular biology applications involving nanotransposons.
Innovation Solution
The development of nanotransposon compositions comprising specific nucleic acid sequences with minimized inter-inverted terminal repeat (ITR) sequences, including a piggyBac transposon design, to facilitate increased transposition and integration into human cells, eliminating the need for foreign DNA and optimizing transposase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional transposon vectors are used, then gene transfer can be achieved, but transposition efficacy and efficiency are insufficient for optimal gene therapy applications
Solution Approach 1:
The patent modifies the structural parameters of the transposon vector by minimizing the inter-ITR sequence length to 1-600 nucleotides (preferably 1-100 nucleotides). This parameter change optimizes transposase accessibility and binding efficiency, thereby resolving the contradiction between transposition efficacy and gene transfer efficiency. The compact inter-ITR region enhances the reliability of gene transfer while maintaining high productivity through improved transposition rates.
2Adaptability or versatility
If foreign DNA sequences are included in transposon vectors, then additional functional elements can be added, but transposition efficiency is reduced
Solution Approach 1:
The patent extracts and removes foreign DNA sequences from the transposon vector design, retaining only the essential inverted terminal repeat (ITR) sequences and the minimal inter-ITR region. This extraction eliminates steric hindrance and structural interference that foreign DNA would cause, thereby restoring high transposition efficiency. The design maintains adaptability by allowing the minimal vector to be combined with various therapeutic payload sequences outside the ITR boundaries.
3Adaptability or versatility
If the inter-ITR sequence is long, then more regulatory elements can be included, but transposase activity and transposition rates decrease
Solution Approach 1:
The patent segments the transposon vector into distinct functional modules: the essential ITR sequences, a minimal inter-ITR core region (1-600 nt), and separate payload/cargo sequences. This segmentation allows the core vector to remain compact for optimal transposase activity, while regulatory elements and therapeutic genes are incorporated as separate modules that do not interfere with the critical ITR-ITR interaction. The segmentation resolves the contradiction by spatially separating elements needed for versatility from those needed for high transposition rate.
Data Source
AI summary
Disclosed are compositions comprising a first nucleic acid sequence comprising: (a) a first inverted terminal repeat (ITR), (b) a second ITR and (c) an intra-ITR sequence, wherein the intra-ITR sequence comprises a transposon sequence, and a second nucleic acid sequence comprising an inter-ITR sequence, wherein the length of the inter-1TR sequence is between 1 and 600 nucleotides, inclusive of the endpoints. Preferably, the compositions are nanotransposons.